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Abstract
Background: Ductal lavage (DL) has been proposed as a minimally-invasive, well-tolerated tool
for obtaining breast epithelial cells for cytological evaluation of breast cancer risk. We report DL
tolerability in BRCA1/2 mutation-positive and -negative women from an IRB-approved research
study.
Methods: 165 BRCA1/2 mutation-positive, 26 mutation-negative and 3 mutation unknown women
underwent mammography, breast MRI and DL. Psychological well-being and perceptions of pain
were obtained before and after DL, and compared with pain experienced during other screening
procedures.
Results: The average anticipated and experienced discomfort rating for DL, 47 and 48 (0–100),
were significantly higher (p  < 0.01) than the anticipated  and  experienced  discomfort of
mammogram (38 and 34), MRI (36 and 25) or nipple aspiration (42 and 27). Women with greater
pre-existing emotional distress experienced more DL-related discomfort than they anticipated.
Women reporting DL-related pain as worse than expected were nearly three times more likely to
refuse subsequent DL than those reporting it as the same or better than expected. Twenty-five
percent of participants refused repeat DL at first annual follow-up.
Conclusion: DL was anticipated to be and experienced as more uncomfortable than other
procedures used in breast cancer screening. Higher underlying psychological distress was
associated with decreased DL tolerability.
Background
Ductal lavage (DL) is a method of collecting breast epithe-
lial cells from the lining of the breast duct by means of a
small-gauge catheter inserted into a ductal orifice on the
nipple to permit direct access to exfoliated breast duct epi-
thelial cells. Information gained from DL might improve
early breast cancer detection, facilitate breast cancer risk
assessment, and yield novel reagents for developing
biomarkers and intermediate end-points in chemopre-
vention trials [1]. Epithelial atypia in cells collected from
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nipple aspirate fluid (NAF) and by random peri-aereolar
fine needle aspiration (RPFNA) has been associated pro-
spectively with an increased risk of non-invasive and inva-
sive breast cancer [2-5]. It was hypothesized that women
with cellular atypia in DL samples would also be at
increased breast cancer risk. However, obtaining adequate
numbers of cells from DL samples for both cytological
review and biomarker development has been a challenge
[6]. Reliably obtaining NAF from all or most women stud-
ied, and acquiring samples with cell counts adequate for
cytologic evaluation (> 10 evaluable cells) from DL speci-
mens has been problematic [1,7-19]. Neither NAF pro-
duction nor 5-year Gail risk > 1.7% [6,20,21] predicted
atypia in DL specimens from high-risk women [9,21]. It is
possible to detect atypia in both NAF-yielding and non-
NAF-yielding ducts from women at high-risk of breast
cancer [6,7,9,12]; however, it is not known whether the
atypia detected by DL will demonstrate an increased pro-
spective risk of breast cancer in women at high genetic risk
of breast cancer, and there is increasing evidence that
reproducibility of cytologic diagnoses in benign duct epi-
thelial specimens and in specimens with atypia found on
DL is only fair-to-poor [6,11,13,17]. Furthermore, if DL is
to be clinically useful, it is essential that the procedure be
well-tolerated, or healthy women will not comply with its
use.
There are several reports of DL-related pain in women at
high risk of breast cancer, but few women who were
known to be BRCA1/2 mutation carriers, and even fewer
who were unaffected BRCA1/2  mutation carriers, were
included in these reports [1,13,18,19]. Visual analogue
scales [1,13,18,19] or Likert-type scales [19] were used to
assess DL-related pain and were administered immedi-
ately after the procedure. The variability in the statistical
methods used for the analyses makes it difficult to com-
pare the findings across the groups. Two groups reported
that DL was well-tolerated [1,18], one group reported that
DL was not well-tolerated [13] and a fourth group
reported that there was more maximal discomfort
reported with DL than with mammogram or breast MRI
[19].
Emotional distress might influence DL tolerability, since
previous general population studies have suggested that
women reporting higher levels of pre-procedure distress
experience greater mammogram-related discomfort [22-
24]. Importantly, unpleasant mammogram-related expe-
riences have been associated with decreased likelihood of
returning for annual breast cancer screening [24,25].
However, previous studies of DL tolerability [1,13,18,19]
have neither assessed emotional distress nor analyzed its
influence on DL tolerability.
The National Cancer Institute Clinical Genetics Branch
Breast Imaging Study (BIS; NCI Protocol 01-C-0009) is a
four-year, prospective cohort study of 200 women from
families with known BRCA1  or  BRCA2  mutations.
BRCA1/2 mutation carriers have an estimated lifetime risk
of breast cancer between 45%–82% [26-29]. Chemopre-
vention is often considered for breast cancer-risk reduc-
tion [30-32] and annual mammography and breast MRI
are employed in the early detection of breast cancer
among high-risk women not choosing risk-reducing mas-
tectomy [33-38]. The overall research goal of the BIS was
to improve early detection of precursor and malignant
breast lesions by evaluating several breast screening proce-
dures: annual DL, mammography, breast MRI, NAF and
clinical breast exam. As the study progressed, we recog-
nized that DL seemed more painful than previously
described. We report these results, compare pain from DL
with other breast screening procedures, and describe asso-
ciations between DL pain, participant characteristics, and
acceptance of annual DL.
Methods
Study Population
Eligible women were between ages 25–56, and  had a
known deleterious BRCA1/2 mutation, or were first- or
second-degree relatives of BRCA1/2 mutation carriers, or
were first- or second-degree relatives of individuals with
BRCA-associated cancers in BRCA1/2  mutation-positive
families. Exclusion criteria included: pregnancy or lacta-
tion within 6 months of enrollment, abnormal CA-125,
bilateral breast cancer, ovarian cancer or breast cancer
(Stage IIB or greater), unless relapse-free for 5 years prior
to enrollment. Participants with a personal history of
DCIS, or Stages I/II breast cancer were eligible, provided
that ≥ 6 months had elapsed since completing primary
therapy. Other exclusion criteria included: a personal his-
tory of other invasive cancer (except for non-melanoma
skin cancer), unless relapse-free for 5 years prior to enroll-
ment; prior bilateral mastectomy; bilateral breast irradia-
tion; weight > 136 kilograms; and gadolinium allergy. DL
was not performed on participants with allergy to lido-
caine or bupivacaine; peri-areolar or other breast surgery
which might disrupt the ductal systems of the breast; a
breast implant or prior silicone injections in the breast;
and active infection or inflammation in the breast to be
studied.
Participants
This analysis includes data from 194 women who were
enrolled during the period June 2002 through May 2006.
Reasons for not performing DL included physician cancel-
lation (n = 13), being ineligible (n = 4), and refusing (n =
5). Participants who did not attend both pre- and post-DL
clinic visits were excluded from the analysis (n = 38).
Excluded women were similar to those analyzed relative
to procedure tolerability ratings, sociodemographic varia-
bles, and other study outcomes, except that excluded
women were more likely to have a history of breast cancerBMC Women's Health 2009, 9:20 http://www.biomedcentral.com/1472-6874/9/20
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and to have had NAF obtained during DL (p < 0.05). The
final study sample included 156 (194 – 38) participants.
Mean participant age was 39.4 (SD  = 8.6); 90% had
attained > high school education. Eighty-five percent were
BRCA1/2  mutation-positive, and 10% reported prior
breast cancer. Ninety-seven percent of subjects were white,
a proportion reflecting the Clinical Genetics Branch refer-
ral pattern.
Procedures
Participants were ascertained from: the NCI-DCEG Famil-
ial Cancer Registry (41/156; 26%) and various healthcare
providers (99/156; 64%), primarily in response to mailed
recruitment letters, or were self-referred from our BIS web-
site 16/156 (10%) [39]. The protocol was reviewed and
approved by the NCI Clinical Center IRB; written
informed consent was obtained from all participants.
Ductal Lavage Protocol
Standard preparation of the breast, including topical anes-
thetic (4% lidocaine cream) applied to the nipple/areola
60 minutes prior to the procedure, was provided to all DL
participants. The nipple/areolar complex surface was gen-
tly probed with a micro dilator tip prior to DL, to confirm
adequate anesthesia. In women who reported probing-
related pain, additional topical anesthesia and/or subcu-
taneous injections of lidocaine around the base of the nip-
ple were administered. Nipple aspiration was performed
to identify all fluid-yielding ducts. We attempted to iden-
tify and cannulate all visible ducts, regardless of NAF sta-
tus (Cytyc Health Corporation, Boxborough MA; Acueity,
Palo Alto, CA). After successful catheter insertion, 3–5 mL
of 1% lidocaine was infused, followed by 20 mL of sterile
normal saline, in 5 mL aliquots. After each aliquot was
infused, the breast was massaged and fluid collected via
the lavage catheter. The location of each lavaged duct was
recorded by threading a blue suture into the duct orifice,
photographing the breast (Figure 1) and storing the photo
in the participant's permanent medical record.
Three clinicians performed the BIS DL procedures: JTL,
adult nurse practitioner, RAG, medical oncologist and LR,
surgical oncologist. The clinicians were trained to perform
ductal lavage using the technique described by Dooley et
al [1]. Most frequently, DL was performed by two clini-
cians working together, alternating between right and left
breast. There was no indication that tolerability changed
during the 4 years required to accrue patients, as the clini-
cians acquired more experience performing ductal lavage.
The preparation of the breast through the completion of
the ductal lavage required approximately one hour for
each breast studied.
Measures
Procedure tolerability
Four indices of breast screening procedure tolerability
were used.
First, women rated each procedure's (mammogram, MRI,
NAF, and DL) discomfort on a 0 to 100 scale, with 100
indicating the worst discomfort imaginable. On Day 1,
participants rated anticipated discomfort before undergoing
any of the screening procedures, and on Day 2 partici-
pants rated experienced  discomfort  after  completing all
screening procedures.
In addition, participants were asked on Day 2 whether dis-
comfort associated with each screening procedure was
worse, the same as, or better than expected.
Women were queried whether the DL-associated discom-
fort was worse, the same, or better than 7 common medi-
cal procedures (flu shot, blood draw, pelvic examination,
mammogram, chest x-ray, Novocaine shot, rectal exam),
and
Participants characterized pain quality by selecting
between the descriptors burning, aching, radiating, sharp,
dull, fullness, or tingling.
Emotional distress
The Brief Symptom Inventory 18 (BSI 18) Global Severity
Index (GSI) was used to quantify overall psychological
distress levels. The BSI 18 has been widely used to assess
distress in medical oncology settings, with good reliability
and validity [40]. It was administered in clinic before par-
ticipants underwent screening procedures and assessed
their levels of distress on that day.
Follow-up DL Screening
Women were asked to return for follow-up DL screening
one year after initial screening. Participants either com-
pleted follow-up DL, cancelled their appointment,
refused follow-up DL, or had not received follow-up DL at
the time of the current analysis for another reason (had
Documentation of DL Procedure Figure 1
Documentation of DL Procedure.BMC Women's Health 2009, 9:20 http://www.biomedcentral.com/1472-6874/9/20
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yet to be scheduled, missed follow-up appointment, left
the study, or became ineligible for follow-up DL due to
partial mastectomy, diagnosis of breast cancer, or preg-
nancy).
Sociodemographic and medical variables
Prior reports have examined age, presence of NAF, history
of breast cancer and BRCA1/BRCA2 mutation status in
relation to DL tolerability; therefore, these variables were
included in the present study [1,13,18,19].
Data analyses
Data analyses were conducted using SPSS Version 15.0
(2006). Bivariate analyses were used to 1) compare con-
tinuous ratings of both anticipated and experienced pro-
cedure discomfort (0–100) between DL and other breast
screening procedures, using paired t-tests, and 2) to exam-
ine continuous ratings of experienced DL discomfort in
relation to study variables (age, history of breast cancer,
BRCA1/BRCA2  mutation status, whether NAF was
obtained during DL, GSI, and whether participants
returned for follow-up DL) using bivariate correlation (r),
independent samples t-tests, or ANOVA. Multivariate
analyses used linear and logistic regression to model con-
tinuous ratings of anticipated and experienced DL dis-
comfort, and to estimate the odds of refusing follow-up
DL. Some participants declined one or more of the screen-
ing procedures; therefore, sample size is reported for each
analysis presented in the Tables.
Results
MRI and NAF were significantly less painful than antici-
pated (p < 0.05); mammogram and DL ratings of experi-
enced discomfort did not differ significantly from
participants' anticipation (Table 1). Figure 2 shows antic-
ipated and experienced discomfort of DL compared with
other study screening procedures for women who com-
pleted both. In all cases, DL discomfort was anticipated to
be, and experienced as, significantly worse than mammo-
gram-, MRI-, and NAF-related discomfort (all p < 0.01),
suggesting that in this cohort, DL was tolerated signifi-
cantly less well than other breast screening procedures.
The majority of women described the discomfort associ-
ated with DL as "sharp" (78%) or "burning" (52%). The
majority of women also reported that DL discomfort was
the same as/worse than discomfort associated with a
Novocaine injection (65%), a blood draw (61%), a pelvic
(59%) or rectal examination (64%).
Bivariate analyses (Table 2) indicated that neither age,
BRCA1/BRCA2  mutation status, nor whether NAF was
obtained during DL were associated with experienced DL
discomfort. Women with a prior breast cancer rated DL
experiences as marginally less painful than women with-
out such a history (p = 0.05). Higher levels of distress were
associated with significantly higher ratings of experienced
DL discomfort (p < 0.05), with women who refused fol-
low-up DL reporting the highest experienced DL discom-
fort (p < 0.01).
Multivariate methods were used to examine anticipated
and experienced DL discomfort ratings (Table 3), and
odds of returning for follow-up DL (Table 4). In these
analyses, age, breast cancer history, whether NAF was
obtained during DL, and GSI scores were entered into the
regression equation in one step. For the linear model of
experienced DL discomfort, anticipated discomfort was
entered as a second step (data for the final model are
shown). The categorical indicator of experienced DL dis-
comfort was included in the logistic model of odds of
refusing follow-up DL. Because of concerns related to
sample size, and the lack of a significant bivariate associa-
Table 1: Paired t-tests for anticipated and experienced discomfort with breast cancer screening procedures (n = 156)
Study Variable Type of Data Sample percent or Mean (SD) P-value
Anticipated mammogram
discomfort (n = 103)
Continuous† 36.8 (18.4)
(median = 30)
p = .388
Experienced mammogram
discomfort (n = 146)
Continuous† 34.4 (23.3)
(median = 30
Anticipated MRI
discomfort (n = 74)
Continuous† 36.3 (17.6)
(median = 30)
p = 0.023
Experienced MRI
discomfort (n = 153)
Continuous† 24.9 (23.7)
(median = 20)
Anticipated NAF
discomfort (n = 94)
Continuous† 41.5 (20.1)
(median = 40)
p = 0.00
Experienced NAF
discomfort (n = 126)
Continuous† 27.1 (24.0)
(median = 20)
Anticipated DL
discomfort (n = 145)
Continuous† 47.2 (20.4)
(median = 50)
p = 0.392
Experienced DL
discomfort (n = 120)
Continuous† 47.7 (23.9)
(median = 50)
†Range for continuous measure of discomfort for all breast screening procedures = (0–100); higher scores indicate greater discomfort.BMC Women's Health 2009, 9:20 http://www.biomedcentral.com/1472-6874/9/20
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tion, BRCA1/2 mutation status was not included in the
multivariate models.
None of the study variables were associated with ratings of
anticipated DL discomfort (Table 3). For experienced dis-
comfort, higher levels of distress (measured by the GSI)
were associated with ratings of greater experienced DL dis-
comfort (β = 0.57; p < 0.05) in Step 1. Adding anticipated
discomfort to the model in Step 2 did not change the
results of Step 1; anticipated DL discomfort was not asso-
ciated with experienced DL discomfort (p  = 0.48),
although the effect for GSI became marginally significant
(p = 0.08) when anticipated discomfort was added to the
model.
We used multivariate logistic regression to model the
odds of refusing follow-up DL (24% of participating
women refused) (Table 4). Women with NAF during DL
Paired t-tests comparing screening procedure discomfort ratings (0–100) (higher scores indicate greater discomfort) Figure 2
Paired t-tests comparing screening procedure discomfort ratings (0–100) (higher scores indicate greater dis-
comfort).BMC Women's Health 2009, 9:20 http://www.biomedcentral.com/1472-6874/9/20
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had marginally lower odds of refusing follow-up DL (OR
= 0.3; p  = 0.06). Higher scores on the GSI (indicating
greater emotional distress) were associated with higher
odds of refusing follow-up DL (OR = 1.1; p  < 0.01).
Women who reported that DL discomfort was worse than
they expected it to be (34% of the study sample) were
more than three times more likely to refuse follow-up DL
(OR = 3.2; p = 0.03) than those reporting DL discomfort
as the same, or better than expected (66% of participants).
Results were consistent in a second regression model in
which we substituted the continuous experienced DL dis-
comfort measure (0–100) for the categorical discomfort
classifier. In the continuous model, the odds of refusing
follow-up DL increased by 5% with every 1-point increase
in experienced DL discomfort ratings (p < 0.01; data not
shown).
Discussion
In this group of women from families at high genetic risk
of breast cancer, experienced DL-related discomfort was
significantly worse than has been reported previously. The
anticipated and experienced discomforts of DL were sig-
nificantly greater than the anticipated and experienced
discomforts related to other common medical procedures
and breast cancer screening methods. The majority of
women described their DL-associated pain as "sharp" or
"burning." Women reporting DL-related pain as worse
than expected were nearly three times more likely to
refuse subsequent DL than those reported it as the same or
better than expected. Women who reported high ratings
of pre-study distress (as measured by the BSI-18) were
more likely to experience greater DL-related discomfort
than women with lower distress ratings.
Several findings have direct impact on the management of
women undergoing DL. First, it seems apparent that for
most women undergoing DL, the current anesthesia pro-
tocol is inadequate. We were able to achieve acceptable
anesthesia at the nipple surface, but passing the catheter
through the constricted ductal sphincter was an important
source of procedure-related pain. Local anesthesia alone
did not relax this sphincter, and nor did using topical
nitro-paste (for smooth muscle relaxation) make a signif-
icant difference.
Table 2: Bivariate associations between DL tolerability and study variables†
Mean rating of experienced DL discomfort (SD) or bivariate correlation (r) p
Age Continuous -0.12 0.18
Personal history of breast cancer Yes 35.0 (18.3) 0.05
No 49.1 (24.1)
BRCA1/2 mutation status Positive 47.8 (23.6) 0.90
Negative 47.0 (26.7)
NAF obtained
during procedure
Yes 47.7 (25.6) 0.99
No 47.7 (23.4)
BSI GSI Continuous 0.20  < 0.05
Returned for follow-up DL Yes 40.5 (19.5)  < 0.01
Refused 61.7 (25.7)
Cancelled 45.9 (25.4)
Other 45.8 (22.4)
†Range for continuous measure of discomfort for all breast screening procedures = (0–100); higher scores indicate greater discomfort.
Table 3: Multivariate linear regression models for discomfort associated with DL
Multivariate linear
regression
Type of Data Anticipated DL discomfort
(n = 122) Model R2 = 0.00
Experienced DL discomfort
(n = 95) Model R2 = 0.08
Step 1 β(SEβ) p β(SEβ) P
Age Continuous 0.14 (0.22) 0.53 -0.33(0.30) 0.27
History of breast cancer Yes
No
-0.45 (6.15)
Ref
0.94 -10.79 (8.01)
Ref
0.18
NAF obtained during
procedure
Yes
No
2.79 (4.55)
Ref
0.54 2.19 (5.79)
Ref
0.71
BSI GSI Continuous 0.11 (0.20) 0.59 0.57 (0.27)  < 0.05
Step 2
Anticipated DL discomfort Continuous n/a n/a 0.09 (0.12) 0.48
BSI GSI Continuous n/a n/a 0.50 (0.28) 0.08BMC Women's Health 2009, 9:20 http://www.biomedcentral.com/1472-6874/9/20
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It is somewhat surprising that younger women and
women without a prior history of breast cancer had simi-
lar reports of discomfort with DL when compared with
older women and women with a prior history of breast
cancer. Compared with other groups who have reported
on DL tolerability [1,13,18,19], our cohort contained
greater numbers of mutation carriers, more young
women, and fewer women with a prior history of breast
cancer. Although we did observe marginally better
reported DL tolerability among women with a history of
breast cancer in bivariate analyses, the small number of
women with a prior history of breast cancer in this cohort
may have limited our ability to demonstrate a statistically
significant difference in DL tolerability between affected
and unaffected participants in regression analyses.
Pain associated with DL has been evaluated by several
groups [1,13,18,19]. Dooley et al., reported on 507
women who had DL performed on at least one breast; 291
had a prior history of breast cancer, 10 had a history of
lobular carcinoma in situ, 199 were high risk due to a Gail
Model risk of ≥ 1.7, 4 were not at high risk of breast can-
cer, and only 3 were BRCA1/2 mutation carriers. A median
pain score of 28 mm on a 0–100 mm visual analogue
scale which was administered immediately after DL was
reported (1). However, 28% of subjects underwent the
procedure in the operating room under general anesthesia
and less than one percent of the subjects were cancer-
unaffected, known BRCA1/2 mutation carriers. No com-
parison of pain scores between subjects who received gen-
eral anesthesia versus those who did not was reported.
Mitchell et al. (20) employed a visual analogue scale
(range 0–10) to record measurements of pain in 52
women with BRCA1/2 mutations. A similar rating of 2.8/
10 was reported immediately after DL, and DL pain was
described as similar to the pain experienced with mam-
mography. As with the previous study (1), more than 50%
of participants were breast cancer survivors. Neither group
reported whether differences existed in measures of pain
between women with a prior history of breast cancer and
unaffected women. It is possible that women who are
breast cancer survivors experience pain differently from
women without a prior history of breast cancer. Neither
group (1,18) reported the acceptance rate of future DL in
their study populations.
DL tolerability was reported in a retrospective study in
women at high risk of breast cancer who had been evalu-
ated as part of a breast cancer screening study [19].
Twenty-two BRCA1/2 mutation carriers rated DL-related
pain on a scale of 1 to 3 (1 = minimal discomfort, 2 =
moderate discomfort, 3 = maximal discomfort), and com-
pared their experience with DL to breast MRI on a scale of
1 to 5 (1 = much better, 2 = somewhat better, 3 = same, 4
= somewhat worse, 5 = much worse). BRCA1/2 mutation
carrier participants more often rated DL as maximally
uncomfortable versus MRI or mammogram, and the max-
imal discomfort ratings for DL vs. mammogram and MRI
combined reached statistical significance (P = 0.04). There
was no difference in reports of pain between breast cancer
survivors and unaffected women; however, the sample
size was small (breast cancer survivors, n = 13; unaffected,
n = 23), and mutation status was not reported. Future
acceptance of DL was not reported in this study popula-
tion.
The reliability and acceptability of DL in 69 women at
high risk of breast cancer due to Gail Model score ≥ l.66 (n
= 38), a family history of breast cancer (n = 53), the pres-
ence of a BRCA1/2 (n = 2), a personal history of abnormal
breast biopsies (atypical hyperplasia, non-invasive or
invasive breast cancer, n = 20) or a prior history of breast
cancer (DCIS/invasive breast cancer, n = 11) was found to
be less than ideal [13]. A visual analogue scale from 0–10
was employed to measure DL pain at visit one and six
months later at the second visit. The mean pain score at
visit one was 4 (range, 0–8) and the mean pain score at
visit 2 was 3 (range, 0–9). After visit one, 70% of the
women who underwent DL reported that they would have
DL again, and if recommended, would undergo the proce-
dure as part of routine early breast cancer detection. How-
Table 4: Multivariate logistic regression model of returning for DL
Multivariate logistic regression Type of Data Odds of refusing DL
(vs. Returned/
Cancelled/Other)(n = 98)
OR (95%CI) p
Age Continuous 1.00 (0.94,107) 0.93
History of breast cancer Yes
No
0.26 (0.03, 2.63)
Ref
0.26
NAF obtained during procedure Yes
No
0.26 (0.06, 1.08)
Ref
0.06
BSI GSI Continuous 1.08 (1.02, 1.15 0.01
Experienced DL discomfort Worse
Same/better
3.19 (1.11, 9.12)
Ref
0.03BMC Women's Health 2009, 9:20 http://www.biomedcentral.com/1472-6874/9/20
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ever, only 52% of these women returned for a second visit.
There were insufficient numbers of known BRCA1/2
mutation carriers within this group of women to deter-
mine whether mutation carriers differ in measures of pain
from other women at high risk of breast cancer.
Emotional distress might influence measures of DL pain
and acceptance, since previous general population studies
have suggested that women describing higher levels of
emotional distress report greater mammogram-related
discomfort [22-24]. Furthermore, unpleasant mammo-
gram-related experiences have been associated with
decreased likelihood of returning for annual breast cancer
screening [24,25]. However, previous studies of DL toler-
ability [1,13,18,19] have neither assessed emotional dis-
tress nor analyzed its influence on DL pain and
acceptance.
Study Strengths
To date, this is the largest group of women with known
BRCA1/2 carrier mutation status to undergo annual DL. It
is also the largest group of unaffected mutation carriers
which has undergone DL as part of an annual breast can-
cer screening program. All procedures were performed by
the same 3 experienced clinicians. Furthermore, this rep-
resents the first formal assessment of emotional distress as
a modifier of DL tolerability, and these data were collected
using a widely-applied, clinically-validated psychometric
tool, the BSI-18. All indices of tolerability were defined
prior to enrollment of the first subject, and the analytic
plan was stipulated in advance. Therefore, the study pro-
vides robust, high-quality information regarding the feasi-
bility of adding DL to current breast cancer screening
strategies for women at high genetic risk of breast cancer.
Our data indicate that poor DL tolerability poses a signif-
icant barrier to its more widespread clinical application.
Limitations
The Breast Imaging Study is a single-institution interven-
tion study of highly-selected women. Women who partic-
ipated in this study are both highly-educated and highly-
motivated to participate in clinical research. It is unlikely
that this group of women is representative of all women
from  BRCA1/2  mutation-positive families or other
healthy women in the general population who are at high
risk of breast cancer. Therefore, our findings may not
apply to a more general population of BRCA1/2 mutation
carriers nor other women at high risk of breast cancer.
However, we doubt that the presence of these highly-
selected women in a study of DL tolerability specifically
designed for woman from BRCA1/2  mutation-positive
families biased the findings. Although a small proportion
(15%) of participants had taken part in multiple prior
NCI HBOC-related clinical research projects [41], the vast
majority were first-time enrollees in a CGB study.
Summary
Our experience suggests that DL is not likely to play a cen-
tral role in breast cancer screening among high-risk
women, because women find it painful, are reluctant to
undergo multiple DL examinations over time, and
because the procedure has also failed to yield large
enough numbers of exfoliated epithelial cells from high-
risk women to permit reliable cytologic diagnosis or to
support translational research activities [7,13]. In addi-
tion, DL is time and personnel intensive; the average time
required to perform bilateral DL was 2 hours and required
two clinicians (MD or NP, plus an assistant). Finally, the
biological plausibility of attempting early diagnosis/risk
stratification on the basis of sampling 1 or 2 ducts from a
20 duct system has not been persuasive. We have discon-
tinued this procedure as a routine component of our
ongoing BIS research protocol.
Conclusion
In conclusion, DL was introduced into clinical practice
only nine years ago; consequently, systematic prospective
studies of its tolerability are limited. Regardless of its ulti-
mate utility as a diagnostic, risk assessment or research
tool, for its use to be practical, it is essential that DL be
well-tolerated. Despite vigorous attempts to obtain satis-
factory local anesthesia (short of doing the procedure in
the operating room), nearly 25% of our participants
refused to repeat the DL one year later.
The current study highlights the important relationships
between measures of emotional distress, experience of DL
discomfort and refusal of subsequent DL. Women who
report high levels of emotional distress just prior to DL are
three times more likely to refuse DL in the future. Addi-
tionally, women who were more distressed were more
likely to report poor DL tolerability, and poor tolerability
was associated with less acceptance of future DL. The iden-
tification of women who are emotionally distressed near
the time of DL provides an opportunity to address the dis-
tress directly, either by using anxiolytic medications,
rescheduling the appointment to a less stressful time, or
referral for emotional counseling prior to DL.
The identification of the quality of pain, e.g., sharp, burn-
ing, allows for refinement in the anesthesia of the breast
nipple. Conscious sedation may be required for optimal
pain relief in women who report emotional distress prior
to DL or in women who experience significant levels of
pain during DL. This, of course, would substantially
increase both the cost and logistical difficulty of applying
this tool in the clinic.
Our experience [17] and others [7] suggests that alterna-
tive strategies aimed at breast cancer early detection, risk
stratification and acquisition of tissue for translationalBMC Women's Health 2009, 9:20 http://www.biomedcentral.com/1472-6874/9/20
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research in high-risk women are required. Multiple core
biopsies of the breast is an option, but one with which
there is neither widespread experience nor ready accept-
ance by either institutional review boards or patients, par-
ticularly if multiple samples over time are required.
However, this technique has been used successfully as a
one-time-only specimen collection strategy in a breast
cancer chemoprevention trial [42]. At present, the leading
candidate for such an alternative is RPFNA of the breast,
as pioneered by Fabian and colleagues [3].
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